Population pharmacokinetics of capecitabine in Chinese breast cancer patients
- Author:
Guofang XU
1
;
Sisen ZHANG
1
;
Ping LIU
1
;
Jiazhuan MEI
1
;
Weiwei LIU
1
;
Guofang XU
2
;
Sisen ZHANG
2
;
Ping LIU
2
;
Jiazhuan MEI
2
;
Weiwei LIU
2
;
Ya'ou LIU
3
;
Qi QI
4
Author Information
- Publication Type:Journal Article
- Keywords: Breast cancer; Capecitabine; HPLC-MS/MS; Population pharmacokinetics model
- From: Chinese Journal of Clinical Pharmacology and Therapeutics 2021;26(5):552-559
- CountryChina
- Language:Chinese
- Abstract: AIM: To investigate the population pharmacokinetic characteristics of capecitabine and its possible influencing factors in Chinese patients of breast cancer. METHODS: 78 cases of Chinese patients with breast cancer were chosen as the objects in this study. Following treatment with capecitabine (0.6 g, 0.15 g/piece, 4 pieces, orally), blood samples were collected and concentrations of capecitabine in plasma were analyzed by high performance liquid chromatography-mass spectrometry (HPLC-MS/MS) method. The nonlinear mixed-effects software (NONMEM) was used to analyze the data and the population pharmacokinetic model was constructed accordingly. RESULTS: The final established model of absorption and elimination is one-compartment model. The clearance (CL/F) in pharmacokinetic formula of the model is as follows: CL/F=291×e
